6533b858fe1ef96bd12b6384
RESEARCH PRODUCT
The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?
Mario CottoneAmbrogio OrlandoFabio Salvatore Macalusosubject
medicine.medical_specialtyCombination therapyDiseaseInflammatory bowel diseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunologic FactorsTreatment FailureProspective cohort studyCrohn's diseasebusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInfliximabInfliximab030220 oncology & carcinogenesisConcomitantImmunology030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drugdescription
Sir, We read with interest the recent work by Peyrin-Biroulet and colleagues on the long-term outcome for patients starting anti-TNF monotherapy for Crohn’s disease [CD] and for those needing the addition of an immunomodulator [IM].1 We agree with the main finding of the study, i.e. starting with anti-TNF monotherapy does not worsen long-term disease outcomes. This is in line with data from the literature2 and with our recent prospective study on the concomitant use of an IM and infliximab [IFX] in patients with CD or ulcerative colitis who have had a primary or secondary non-response to IFX monotherapy3: …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-04-30 | Journal of Crohn'scolitis |